UK's Verici Dx H1 revenue dips as licensing income falls; adjusted EBITDA loss widens
UK's Verici Dx H1 revenue dips as licensing income falls; adjusted EBITDA loss widens
Overview
UK transplant diagnostics firm's H1 2026 revenue declined slightly as licensing revenue fell
Adjusted EBITDA loss widened in H1 2026 compared to prior year
Company completed $3.4 mln equity fundraise in June, proposes further raise to support growth
Outlook
Company expects further strong growth in Q4 2026 from expanded sales team and new centers
Company anticipates accelerating growth in Q4 2026 as new centers become recurring customers
Company expects new products to add revenue lines in FY 2027 and beyond
Result Drivers
TUTIVIA TESTING GROWTH - Co said strong growth in Tutivia testing volumes drove direct revenue in H1 2026
PAYOR ACCESS - Co said new BCBS Illinois agreement expanded in-network access for Tutivia tests
MARKETING SPEND - Increased sales support and marketing spend aimed at raising awareness of Tutivia test
Company press release: ID:nRSd0480Xa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Adjusted EBITDA |
| -$3.50 mln |
|
H1 EBIT |
| -$4.00 mln |
|
H1 Pretax Loss |
| $4.03 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Verici DX PLC is GBp1.23, about 486.2% above its September 29 closing price of GBp0.21
Reuters Recommended Reads
Sept 30 - UK's Spire Healthcare H1 hit by lower NHS activity, higher costs
Sept 30 - UK's Creo Medical H1 revenue surges, loss narrows
Sept 30 - UK's NAHL Group H1 revenue rises on personal injury business growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)